GuidoMarcucciMD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Chief, Division of Leukemia; Chair and Professor, Department of Hematologic Malignancies Translational Science; Director, Gehr Family Center for Leukemia Research City of Hope Comprehensive Cancer Center

Join to view full profile

Dr. Marcucci is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Marcucci's full profile

Already have an account?

Office
Division of Leukemia
1500 East Duarte Road
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 626-389-3061

Summary

Dr. Guido Marcucci is Medical Oncologist is affiliated with City of Hope's Helford Clinical Research Hospital. He is Chief of the Division of Leukemia, Chair and Professor of the Dept. of Hematologic Malignancies Translational Science, Director of the Gehr Family Center for Leukemia Research, and Director of the Hematopoietic Tissue Biorepository. He is experienced in hematologic oncology, leukemia, hematopoietic stem cell transplantation, flow cytometry, cytogenetics, and drug delivery systems.

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1997 - 1998
University at BuffaloFellowship, Hematology and Medical Oncology, 1995 - 1997
SUNY at Buffalo Graduate Medical-Dental Education Consortium (Millard Fillmore)Residency, Internal Medicine, 1990 - 1993
University of Cattolica del Sacro CuoreClass of 1987

Certifications & Licensure

CA State Medical License 2015 - 2024
OH State Medical License 1997 - 2016
NY State Medical License 1995 - 1998
PA State Medical License 1993 - 1996
American Board of Internal Medicine Medical Oncology

Clinical Trials

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Start of enrollment: 1999 Oct 01
Completed
Phase 1
FR901228 in Treating Patients With Hematologic Cancer Start of enrollment: 2002 Jan 01
Completed
Phase 1
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia Start of enrollment: 2002 Apr 01
Completed
Phase 1
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2003 Sep 01
Completed
Phase 1
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2003 Dec 01
Completed
Phase 3
Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2007 May 01
Completed
Phase 2
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2008 Apr 01
Completed
Phase 1
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2008 Jun 01
Completed
Phase 1
Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia Start of enrollment: 2006 May 01
Active, not recruiting
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2010 Aug 01
Completed
Phase 1
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler Start of enrollment: 2011 Oct 01
Terminated
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Sep 17
Completed
Phase 1
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia Start of enrollment: 2017 Aug 21
Active, not recruiting
Phase 1
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory Start of enrollment: 2020 May 04
Recruiting
Phase 1
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax Start of enrollment: 2022 Jul 29
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

423 citations
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion
Rui Su, Lei Dong, Yangchan Li, Min Gao, Li Han
Cancer Cell. 2020-07-13
738 citations
R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling
Rui Su, Lei Dong, Chenying Li, Sigrid Nachtergaele, Mark Wunderlich
Cell. 2018-01-11
181 citations
R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis.
Ying Qing, Lei Dong, Lei Gao, Chenying Li, Yangchan Li
Molecular Cell. 2021-03-04

Journal Articles

Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia
Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature

Abstracts/Posters

Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug ResistanceClinically Relevant Abstract
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
HDAC8 Promotes MLL-Rearranged Acute Myeloid Leukemia By Inhibiting p53 Acetylation
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia...
Guido Marcucci, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in AdultsClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell MalignanciesClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
CD84: A Potential Novel Therapeutic Target in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Rando...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Authored Content

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationJune 2017

Press Mentions

Cellworks Biosimulation Study Reveals Biomarkers That Predict Response to Hypomethylating Agents and Patient Survival in MDSDecember 12th, 2022
myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients Than Physician Prescribed TreatmentDecember 14th, 2021
myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients Than Physician Prescribed TreatmentDecember 14th, 2021
Join now to see all